Atherosclerotic Cardiovascular Disease Ascvd clinical trials

Explore recruiting atherosclerotic cardiovascular disease ascvd clinical trials.

Recruiting atherosclerotic cardiovascular disease ascvd studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atherosclerotic Cardiovascular Disease Ascvd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) with background inclisiran in participants with atherosclerotic cardiovascular disease, and elevated LDL-C and Lp(a)

Germany, Netherlands, Spain, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial

Belgium, Slovenia, Spain, Hungary, France, Poland +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)

Romania, Croatia, Lithuania, Hungary, Sweden, Austria +18 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Slovakia, Poland, Greece, Netherlands, Germany, Czechia +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

Slovakia, Denmark, Portugal, Czechia, Poland, Greece +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)

Lithuania, Estonia, Croatia, Latvia, Sweden, Denmark +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Atherosclerotic Cardiovascular Disease Ascvd trials by city

Atherosclerotic Cardiovascular Disease Ascvd clinical trials

Recruiting atherosclerotic cardiovascular disease ascvd studies right now

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Penn Medicine Healthy Heart

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

Also recruiting in Europe

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) with background inclisiran in participants with atherosclerotic cardiovascular disease, and elevated LDL-C and Lp(a)

A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial

A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)

Atherosclerotic Cardiovascular Disease Ascvd trials by city

Other conditions